The complaint, spearheaded by the Law Offices of Howard G. Smith, alleges that Hims & Hers engaged in deceptive practices between August 4, 2025, and July 29, 2026. According to the filing, the company failed to disclose that it shared sensitive consumer health data with third-party advertising platforms. Furthermore, the suit claims the firm billed customers for prescriptions immediately following intake form submissions, contradicting public assurances that patients would consult with providers to determine appropriate treatments before charges were processed.

These undisclosed operations reportedly invited heightened regulatory scrutiny and the potential for substantial financial penalties. The lawsuit argues that the company’s public statements during this period regarding its business prospects lacked a reasonable basis, effectively misleading shareholders. Investors who held stock during the specified timeframe are not required to take immediate action to remain part of the class, though those seeking to act as lead plaintiffs must contact the representing firm before the November deadline.